Gordon Davis
Overview
Explore the profile of Gordon Davis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
172
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Piccini J, Abraham W, Dufton C, Carroll I, Healey J, Van Veldhuisen D, et al.
JACC Heart Fail
. 2019 May;
7(7):586-598.
PMID: 31042551
Objectives: The purpose of this study was to compare the effectiveness of bucindolol with that of metoprolol succinate for the maintenance of sinus rhythm in a genetically defined heart failure...
2.
Parikh K, Fiuzat M, Davis G, Neely M, Blain-Nelson P, Whellan D, et al.
Circ Genom Precis Med
. 2018 Oct;
11(8):e002210.
PMID: 30354340
Background In heart failure (HF) with reduced ejection fraction, 2 clinical trials, the BEST (β-Blocker Evaluation of Survival Trial) and HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise...
3.
Breathett K, Allen L, Udelson J, Davis G, Bristow M
Circ Heart Fail
. 2016 Sep;
9(10).
PMID: 27656000
Background: Left ventricular remodeling, as commonly measured by left ventricular ejection fraction (LVEF), is associated with clinical outcomes. Although change in LVEF over time should reflect response to therapy and...
4.
Taylor M, Sun A, Davis G, Fiuzat M, Liggett S, Bristow M
JACC Heart Fail
. 2014 Dec;
2(6):561-72.
PMID: 25443111
Because of its comparatively recent evolution, Homo sapiens exhibit relatively little within-species genomic diversity. However, because of genome size, a proportionately small amount of variation creates ample opportunities for both...
5.
Aleong R, Sauer W, Davis G, Bristow M
Am J Med
. 2014 Jun;
127(10):963-71.
PMID: 24931393
Background: Atrial fibrillation and heart failure with reduced left ventricular ejection fraction have interrelated pathophysiologies. New-onset atrial fibrillation in heart failure patients has been associated with increased mortality, but has...
6.
Aleong R, Sauer W, Davis G, Murphy G, Port J, Anand I, et al.
JACC Heart Fail
. 2013 Oct;
1(4):338-344.
PMID: 24159564
Objectives: This study assessed the impact of bucindolol, a beta-blocker/sympatholytic agent, on the development of atrial fibrillation (AF) in advanced chronic heart failure with reduced left ventricular ejection fraction (HFREF)...
7.
Kao D, Davis G, Aleong R, OConnor C, Fiuzat M, Carson P, et al.
Eur J Heart Fail
. 2012 Dec;
15(3):324-33.
PMID: 23223178
Aims: There is little evidence of beta-blocker treatment benefit in patients with heart failure and reduced left ventricular ejection fraction (HFREF) and atrial fibrillation (AF). We investigated the effects of...
8.
OConnor C, Fiuzat M, Carson P, Anand I, Plehn J, Gottlieb S, et al.
PLoS One
. 2012 Oct;
7(10):e44324.
PMID: 23071495
Background: Pharmacogenetics involves complex interactions of gene products affecting pharmacodynamics and pharmacokinetics, but there is little information on the interaction of multiple genetic modifiers of drug response. Bucindolol is a...
9.
Boezaart A, Davis G, Le-Wendling L
Curr Opin Anaesthesiol
. 2012 Oct;
25(6):665-72.
PMID: 23032682
Purpose Of Review: Ambulatory surgery continues to expand in scope and volume. Part of this development is supported by improvements in anesthesia care, especially in the realm of postoperative analgesia,...
10.
Carson P, Fiuzat M, OConnor C, Anand I, Plehn J, Lindenfeld J, et al.
Am Heart J
. 2010 Oct;
160(4):649-54.
PMID: 20934558
Background: End point committees are routinely used to adjudicate efficacy and safety end points in clinical trials. The 2,708-patient β-Blocker Evaluation of Survival Trial (BEST) originally determined hospitalization type via...